Full text
Earnings transcript
Read the complete earnings call transcript.
TEVA
Teva Pharmaceutical Industries Limited
$41.5
0.39
(0.95%)
| Exchange: | NYSE |
| Market Cap: | 48.36B |
| Shares Outstanding: | 436.912M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Richard D. Francis | |||||
| Full Time Employees: | 32008 | |||||
| Address: |
| |||||
| Website: | https://www.tevapharm.com |
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company’s diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington’s disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Click to read more…
Revenue Segmentation
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | 48.4B | 62.2 | 20.8 | 9.0% |
 HLN | Haleon plc | 44.5B | 19.3 | 18.1 | 6.5% |
 TAK | Takeda Pharmaceutical Company Limited | 62.2B | 51.2 | 43.3 | 2.4% |
 ZTS | Zoetis Inc. | 32.8B | 12.3 | 12.8 | 21.6% |
 VTRS | Viatris Inc. | 21.4B | — | 7.4 | -0.2% |
 ELAN | Elanco Animal Health Incorporated | 11.8B | — | 20.7 | 3.9% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 15,845,000 | 16,544,000 | 17,257,000 |
| Gross Profit | 7,645,000 | 8,063,000 | 8,938,000 |
| EBITDA | 1,558,000 | 4,431,000 | 3,141,000 |
| Operating Income | 433,000 | -303,000 | 2,157,000 |
| Net Income | -559,000 | -1,639,000 | 1,410,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 43,479,000 | 39,326,000 | 40,747,368 |
| Total Liabilities | 35,353,000 | 33,606,000 | 32,833,491 |
| Total Stockholders Equity | 7,506,000 | 5,380,000 | 7,909,877 |
| Total Debt | 20,153,000 | 18,079,000 | 17,381,731 |
| Cash and Cash Equivalents | 3,226,000 | 3,300,000 | 3,555,945 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,368,000 | 1,247,000 | 1,649,000 |
| Capital Expenditure | -526,000 | -498,000 | -501,000 |
| Free Cash Flow | 842,000 | 749,000 | 1,148,000 |
| Net Income | -615,000 | -1,959,000 | 1,410,000 |
| Net Change in Cash | 393,000 | 73,000 | 256,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 18,364,571.871 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 19,261,995.659 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 18,795,057.885 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 7,267,744.731 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 7,624,847.813 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 7,439,044.064 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 4,802,907.154 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 5,110,186.234 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 4,950,306.334 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 4,142,206.278 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 4,344,623.981 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 4,239,304.206 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 4.220 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 4.360 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 4.090 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 5 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates TEVA intrinsic value between $44.57 – $60.70 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about TEVA valuation
Is Teva Pharmaceutical Industries Limited (TEVA) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Teva Pharmaceutical Industries Limited (TEVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TEVA a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TEVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TEVA’s P/E ratio?
You can see TEVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TEVA?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TEVA a good long-term investment?
Whether TEVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TEVA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.95
Trading Metrics:
| Open: | 41.24 | Previous Close: | 41.11 | |
| Day Low: | 40.97 | Day High: | 41.7 | |
| Year Low: | 18.83 | Year High: | 42.02 | |
| Price Avg 50: | 38.13 | Price Avg 200: | 34.1 | |
| Volume: | 5.936M | Average Volume: | 5.558M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
